Mammospheres of letrozole-resistant breast cancer cells enhance breast cancer aggressiveness

Patel,Jankiben R.; Gallegos,Karen M.; Walker,Rashidra R.; Davidson,A. Michael; Davenport,Ian; Tilghman,Syreeta L.

doi:10.3892/ol.2021.12881

Mammospheres of letrozole-resistant breast cancer cells enhance breast cancer aggressiveness

Authors:
- Jankiben R. Patel
- Karen M. Gallegos
- Rashidra R. Walker
- A. Michael Davidson
- Ian Davenport
- Syreeta L. Tilghman
View Affiliations

Affiliations: Division of Basic Sciences, College of Pharmacy and Pharmaceutical Sciences, Florida A&M University, Tallahassee, FL 32307, USA, Division of Biological and Public Health Sciences, Department of Biology, College of Arts and Sciences, Xavier University of Louisiana, New Orleans, LA 70125, USA
Published online on: June 28, 2021 https://doi.org/10.3892/ol.2021.12881
Article Number: 620

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Aromatase inhibitors (AIs), such as letrozole, are considered as first‑line treatment for estrogen receptor‑positive breast cancer in postmenopausal women. Despite the successful use of letrozole, resistance to therapy, tumor relapse and metastasis remain principal causes of patient mortality. Although there is no therapy currently available for AI‑resistant breast cancer, previous reports have demonstrated that AI resistance is associated with hormone independence, increased growth factor signaling, enhanced cellular motility and epithelial to mesenchymal transition (EMT). This suggests a convergence of EMT and cancer stem cells (CSCs) in endocrine resistance. The present study evaluated the contribution of mammospheres in letrozole‑resistant breast cancer by characterizing mammospheres and their potential impact on cellular motility. Ovariectomized immunocompromised female mice were inoculated in the mammary fat pad with either letrozole‑resistant MCF‑7 cells (LTLT‑Ca) or letrozole‑sensitive MCF‑7 cells (AC‑1). Subsequently, intratumoral CSC marker expression was assessed by immunohistochemistry. The results indicated that LTLT‑Ca tumors were CD44⁺/CD24⁺, while AC‑1 tumors presented low CD44/CD24 expression. Since mammosphere formation depends on CSCs, both cell lines were cultured either adherently (2D) or as mammospheres (3D) to assess the CD44/CD24 protein expression profile. When 3D culturing both cell lines, higher expression levels of CD44 and CD24 were observed when compared with their adherent counterparts, with the most robust change observed in the LTLT‑Ca cell line. To quantitate the breast cancer stem cell activity, mammosphere formation assays were performed, and the LTLT‑Ca cells formed mammospheres at a 3.4‑fold higher index compared with AC‑1 cells. Additionally, targeted gene expression arrays were conducted to compare the LTLT‑Ca 3D and 2D cells, revealing that LTLT‑Ca 3D cells displayed decreased expression levels of genes involved in cell adhesion and tumor suppression (e. g., E‑cadherin, caveolin 1 and β‑catenin). To validate this finding, wound healing assays were performed, and LTLT‑Ca mammospheres exhibited a 70% wound closure, whereas AC‑1 mammospheres exhibited a 39% wound closure. Collectively, the present findings demonstrated a strong association between AI‑resistant mammospheres and an increased propensity for migration, which may be indicative of a poor prognosis.

View Figures

View References

1	Gilani RA, Kazi AA, Shah P, Schech AJ, Chumsri S, Sabnis G, Jaiswal AK and Brodie AH: The importance of her2 signaling in the tumor-initiating cell population in aromatase inhibitor-resistant breast cancer. Breast Cancer Res Treat. 135:681–692. 2012. View Article : Google Scholar : PubMed/NCBI
2	Brodie A, Jelovac D, Macedo L, Sabnis G, Tilghman S and Goloubeva O: Therapeutic observations in MCF-7 aromatase xenografts. Clin Cancer Res. 11:884s–888s. 2005.PubMed/NCBI
3	Brodie A, Jelovac D, Sabnis G, Long B, Macedo L and Goloubeva O: Model systems: Mechanisms involved in the loss of sensitivity to letrozole. J Steroid Biochem Mol Biol. 95:41–48. 2005. View Article : Google Scholar : PubMed/NCBI
4	Jelovac D, Sabnis G, Long BJ, Macedo L, Goloubeva OG and Brodie AM: Activation of mitogen-activated protein kinase in xenografts and cells during prolonged treatment with aromatase inhibitor letrozole. Cancer Res. 65:5380–5389. 2005. View Article : Google Scholar : PubMed/NCBI
5	Sabnis G and Brodie A: Adaptive changes results in activation of alternate signaling pathways and resistance to aromatase inhibitor resistance. Mol Cell Endocrinol. 340:142–147. 2011. View Article : Google Scholar : PubMed/NCBI
6	Sabnis G, Schayowitz A, Goloubeva O, Macedo L and Brodie A: Trastuzumab reverses letrozole resistance and amplifies the sensitivity of breast cancer cells to estrogen. Cancer Res. 69:1416–1428. 2009. View Article : Google Scholar : PubMed/NCBI
7	Tilghman SL, Townley I, Zhong Q, Carriere PP, Zou J, Llopis SD, Preyan LC, Williams CC, Skripnikova E, Bratton MR, et al: Proteomic signatures of acquired letrozole resistance in breast cancer: Suppressed estrogen signaling and increased cell motility and invasiveness. Mol Cell Proteomics. 12:2440–2455. 2013. View Article : Google Scholar : PubMed/NCBI
8	Kalluri R and Weinberg RA: The basics of epithelial-mesenchymal transition. J Clin Invest. 119:1420–1428. 2009. View Article : Google Scholar : PubMed/NCBI
9	Tsai JH and Yang J: Epithelial-mesenchymal plasticity in carcinoma metastasis. Genes Dev. 27:2192–2206. 2013. View Article : Google Scholar : PubMed/NCBI
10	Gupta PB, Chaffer CL and Weinberg RA: Cancer stem cells: Mirage or reality? Nat Med. 15:1010–1012. 2009. View Article : Google Scholar : PubMed/NCBI
11	Mani SA, Guo W, Liao MJ, Eaton EN, Ayyanan A, Zhou AY, Brooks M, Reinhard F, Zhang CC, Shipitsin M, Campbell LL, Polyak K, Brisken C, Yang J and Weinberg RA: The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell. 133:704–715. 2008. View Article : Google Scholar : PubMed/NCBI
12	Al-Hajj M and Clarke MF: Self-renewal and solid tumor stem cells. Oncogene. 23:7274–7282. 2004. View Article : Google Scholar : PubMed/NCBI
13	Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ and Clarke MF: Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci USA. 100:3983–3988. 2003. View Article : Google Scholar : PubMed/NCBI
14	Armstrong AJ, Marengo MS, Oltean S, Kemeny G, Bitting RL, Turnbull JD, Herold CI, Marcom PK, George DJ and Garcia-Blanco MA: Circulating tumor cells from patients with advanced prostate and breast cancer display both epithelial and mesenchymal markers. Mol Cancer Res. 9:997–1007. 2011. View Article : Google Scholar : PubMed/NCBI
15	van der Horst G, Bos L and van der Pluijm G: Epithelial plasticity, cancer stem cells, and the tumor-supportive stroma in bladder carcinoma. Mol Cancer Res. 10:995–1009. 2012. View Article : Google Scholar : PubMed/NCBI
16	Weiswald LB, Bellet D and Dangles-Marie V: Spherical cancer models in tumor biology. Neoplasia. 17:1–15. 2015. View Article : Google Scholar : PubMed/NCBI
17	Serrano M: The ink4a/arf locus in murine tumorigenesis. Carcinogenesis. 21:865–869. 2000. View Article : Google Scholar : PubMed/NCBI
18	Cicalese A, Bonizzi G, Pasi CE, Faretta M, Ronzoni S, Giulini B, Brisken C, Minucci S, Di Fiore PP and Pelicci PG: The tumor suppressor p53 regulates polarity of self-renewing divisions in mammary stem cells. Cell. 138:1083–1095. 2009. View Article : Google Scholar : PubMed/NCBI
19	Dey D, Saxena M, Paranjape AN, Krishnan V, Giraddi R, Kumar MV, Mukherjee G and Rangarajan A: Phenotypic and functional characterization of human mammary stem/progenitor cells in long term culture. PLoS One. 4:e53292009. View Article : Google Scholar : PubMed/NCBI
20	Manuel Iglesias J, Beloqui I, Garcia-Garcia F, Leis O, Vazquez-Martin A, Eguiara A, Cufi S, Pavon A, Menendez JA, Dopazo J and Martin AG: Mammosphere formation in breast carcinoma cell lines depends upon expression of e-cadherin. PLoS One. 8:e772812013. View Article : Google Scholar : PubMed/NCBI
21	Gupta A, Mehta R, Alimirah F, Peng X, Murillo G, Wiehle R and Mehta RG: Efficacy and mechanism of action of proellex, an antiprogestin in aromatase overexpressing and letrozole resistant t47d breast cancer cells. J Steroid Biochem Mol Biol. 133:30–42. 2013. View Article : Google Scholar : PubMed/NCBI
22	Capes-Davis A, Reid YA, Kline MC, Storts DR, Strauss E, Dirks WG, Drexler HG, MacLeod RA, Sykes G, Kohara A, et al: Match criteria for human cell line authentication: Where do we draw the line? Int J Cancer. 132:2510–2519. 2013. View Article : Google Scholar : PubMed/NCBI
23	Johnson KP, Yearby LA, Stoute D, Burow ME, Rhodes LV, Gray M, Carriere P, Tilghman SL, McLachlan JA, Ochieng J, et al: In vitro and in vivo evaluation of novel anticancer agents in triple negative breast cancer models. J Health Care Poor Underserved. 24 (Suppl 1):104–111. 2013. View Article : Google Scholar : PubMed/NCBI
24	Carriere PP, Llopis SD, Naiki AC, Nguyen G, Phan T, Nguyen MM, Preyan LC, Yearby L, Pratt J, Burks H, et al: Glyceollin i reverses epithelial to mesenchymal transition in letrozole resistant breast cancer through zeb1. Int J Environ Res Public Health. 13:ijerph130100102016.PubMed/NCBI
25	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative pcr and the 2(−delta delta c(t)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
26	Pfaffl MW, Lange IG, Daxenberger A and Meyer HH: Tissue-specific expression pattern of estrogen receptors (ER): Quantification of ER alpha and ER beta mRNA with real-time RT-PCR. Acta Pathol Microbiol Scand Suppl. 109:345–355. 2001. View Article : Google Scholar : PubMed/NCBI
27	Creighton CJ, Li X, Landis M, Dixon JM, Neumeister VM, Sjolund A, Rimm DL, Wong H, Rodriguez A, Herschkowitz JI, et al: Residual breast cancers after conventional therapy display mesenchymal as well as tumor-initiating features. Proc Natl Acad Sci USA. 106:13820–13825. 2009. View Article : Google Scholar : PubMed/NCBI
28	Dontu G, Abdallah WM, Foley JM, Jackson KW, Clarke MF, Kawamura MJ and Wicha MS: In vitro propagation and transcriptional profiling of human mammary stem/progenitor cells. Genes Dev. 17:1253–1270. 2003. View Article : Google Scholar : PubMed/NCBI
29	Du L, Wang H, He L, Zhang J, Ni B, Wang X, Jin H, Cahuzac N, Mehrpour M, Lu Y and Chen Q: Cd44 is of functional importance for colorectal cancer stem cells. Clin Cancer Res. 14:6751–6760. 2008. View Article : Google Scholar : PubMed/NCBI
30	Ricardo S, Vieira AF, Gerhard R, Leitao D, Pinto R, Cameselle-Teijeiro JF, Milanezi F, Schmitt F and Paredes J: Breast cancer stem cell markers cd44, cd24 and aldh1: Expression distribution within intrinsic molecular subtype. J Clin Pathol. 64:937–946. 2011. View Article : Google Scholar : PubMed/NCBI
31	Li W, Ma H, Zhang J, Zhu L, Wang C and Yang Y: Unraveling the roles of cd44/cd24 and aldh1 as cancer stem cell markers in tumorigenesis and metastasis. Sci Rep. 7:138562017. View Article : Google Scholar : PubMed/NCBI
32	Li W, Ma H, Zhang J, Zhu L, Wang C and Yang Y: Author correction: Unraveling the roles of cd44/cd24 and aldh1 as cancer stem cell markers in tumorigenesis and metastasis. Sci Rep. 8:42762018. View Article : Google Scholar : PubMed/NCBI
33	Oliveras-Ferraros C, Vazquez-Martin A, Martin-Castillo B, Cufí S, Del Barco S, Lopez-Bonet E, Brunet J and Menendez JA: Dynamic emergence of the mesenchymal cd44(pos)cd24(neg/low) phenotype in her2-gene amplified breast cancer cells with de novo resistance to trastuzumab (herceptin). Biochem Biophys Res Commun. 397:27–33. 2010. View Article : Google Scholar : PubMed/NCBI
34	Simpkins SA, Hanby AM, Holliday DL and Speirs V: Clinical and functional significance of loss of caveolin-1 expression in breast cancer-associated fibroblasts. J Pathol. 227:490–498. 2012. View Article : Google Scholar : PubMed/NCBI
35	Sloan EK, Ciocca DR, Pouliot N, Natoli A, Restall C, Henderson MA, Fanelli MA, Cuello-Carrión FD, Gago FE and Anderson RL: Stromal cell expression of caveolin-1 predicts outcome in breast cancer. Am J Pathol. 174:2035–2043. 2009. View Article : Google Scholar : PubMed/NCBI
36	Witkiewicz AK, Dasgupta A, Sotgia F, Mercier I, Pestell RG, Sabel M, Kleer CG, Brody JR and Lisanti MP: An absence of stromal caveolin-1 expression predicts early tumor recurrence and poor clinical outcome in human breast cancers. Am J Pathol. 174:2023–2034. 2009. View Article : Google Scholar : PubMed/NCBI
37	Trimmer C, Sotgia F, Whitaker-Menezes D, Balliet RM, Eaton G, Martinez-Outschoorn UE, Pavlides S, Howell A, Iozzo RV, Pestell RG, et al: Caveolin-1 and mitochondrial sod2 (mnsod) function as tumor suppressors in the stromal microenvironment: A new genetically tractable model for human cancer associated fibroblasts. Cancer Biol Ther. 11:383–394. 2011. View Article : Google Scholar : PubMed/NCBI
38	Lu Z, Ghosh S, Wang Z and Hunter T: Downregulation of caveolin-1 function by egf leads to the loss of e-cadherin, increased transcriptional activity of beta-catenin, and enhanced tumor cell invasion. Cancer Cell. 4:499–515. 2003. View Article : Google Scholar : PubMed/NCBI
39	Dolled-Filhart M, McCabe A, Giltnane J, Cregger M, Camp RL and Rimm DL: Quantitative in situ analysis of beta-catenin expression in breast cancer shows decreased expression is associated with poor outcome. Cancer Res. 66:5487–5494. 2006. View Article : Google Scholar : PubMed/NCBI
40	Gomes IM, Maia CJ and Santos CR: Steap proteins: From structure to applications in cancer therapy. Mol Cancer Res. 10:573–587. 2012. View Article : Google Scholar : PubMed/NCBI
41	Xie J, Yang Y, Sun J, Jiao Z, Zhang H and Chen J: Steap1 inhibits breast cancer metastasis and is associated with epithelial-mesenchymal transition procession. Clin Breast Cancer. 19:e195–e207. 2019. View Article : Google Scholar : PubMed/NCBI
42	Maia CJ, Socorro S, Schmitt F and Santos CR: Steap1 is over-expressed in breast cancer and down-regulated by 17beta-estradiol in mcf-7 cells and in the rat mammary gland. Endocrine. 34:108–116. 2008. View Article : Google Scholar : PubMed/NCBI
43	Wang G, Huang W, Li W, Chen S, Chen W, Zhou Y, Peng P and Gu W: Tfpi-2 suppresses breast cancer cell proliferation and invasion through regulation of erk signaling and interaction with actinin-4 and myosin-9. Sci Rep. 8:144022018. View Article : Google Scholar : PubMed/NCBI